Source link : https://www.newshealth.biz/health-news/benefits-of-drug-combo-in-myeloma-maintenance-shown-in-relevant-subgroups/
A post hoc analysis of the phase III AURIGA study showed that the addition of daratumumab (Darzalex) to lenalidomide (Revlimid) for multiple myeloma in the post-transplant maintenance setting improved minimal residual disease (MRD)-negativity conversion rates compared with lenalidomide alone across clinically relevant subgroups. In this exclusive MedPage Today video, Laahn Foster, MD, of the University […]
Author : News Health
Publish date : 2024-12-16 16:03:55
Copyright for syndicated content belongs to the linked Source.
inHealth